A Time to Event Model for the Immunogenicity of Monoclonal Antibody X

被引：0
|
作者：
Li, Dan [1 ]
Zhang, Yaping [2 ]
Schwendeman, Anna [1 ]
Ruppel, Jane [3 ]
Winter, Helen [2 ]
Jin, Jin Y. [2 ]
Deng, Rong [2 ]
机构：
[1] Univ Michigan, Dept Pharmaceut Sci, Ann Arbor, MI 48109 USA
[2] Genentech Inc, Dept Clin Pharmacol, San Francisco, CA 94080 USA
[3] Genentech Inc, Dept Bioanalyt Sci, San Francisco, CA 94080 USA
来源：
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS | 2017年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
W-019
引用
收藏
页码：S105 / S105
页数：1
相关论文
共 50 条
  • [1] Immunogenicity of monoclonal antibody: Causes, consequences, and control strategies
    Asmani, Ahmad Zafran Amin
    Zainuddin, Ahmad Faris Fahmi
    Murad, Nadhirah Ahmad Azmi
    Darwis, Nur Hidayati Mohd
    Suhaimi, Nur Suhaida
    Zaini, Erizal
    Taher, Muhammad
    Susanti, Deny
    Khotib, Junaidi
    PATHOLOGY RESEARCH AND PRACTICE, 2024, 263
  • [2] Monoclonal antibody-derived peptides carrying chemical modifications induce immunogenicity in a transgenic mouse model
    Peters, Bjoern
    Wang, Y. John
    Iglesias, Antonio
    Schoneich, Christian
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 255
  • [3] Investigation of the Immunogenicity of Different Types of Aggregates of a Murine Monoclonal Antibody in Mice
    Freitag, Angelika J.
    Shomali, Maliheh
    Michalakis, Stylianos
    Biel, Martin
    Siedler, Michael
    Kaymakcalan, Zehra
    Carpenter, John F.
    Randolph, Theodore W.
    Winter, Gerhard
    Engert, Julia
    PHARMACEUTICAL RESEARCH, 2015, 32 (02) : 430 - 444
  • [4] Immunogenicity Risk Assessment of Spontaneously Occurring Therapeutic Monoclonal Antibody Aggregates
    Swanson, Michael D.
    Rios, Shantel
    Mittal, Sarita
    Soder, George
    Jawa, Vibha
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [5] TOXICITY AND IMMUNOGENICITY OF MONOCLONAL ANTIMELANOMA ANTIBODY RICIN A CHAIN IMMUNOTOXIN IN RATS
    STOUDEMIRE, JB
    MISCHAK, RP
    HARKONEN, WS
    JOURNAL OF CELLULAR BIOCHEMISTRY, 1987, : 192 - 192
  • [6] Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics
    Tatarewicz, Suzanna
    Miller, Jill M.
    Swanson, Steven J.
    Moxness, Michael S.
    JOURNAL OF IMMUNOLOGICAL METHODS, 2010, 357 (1-2) : 10 - 16
  • [7] Immunogenicity of a brominated protein and successive establishment of a monoclonal antibody to dihalogenated tyrosine
    Kato, Y
    Kawai, Y
    Morinaga, H
    Kondo, H
    Dozaki, N
    Kitamoto, N
    Osawa, T
    FREE RADICAL BIOLOGY AND MEDICINE, 2005, 38 (01) : 24 - 31
  • [8] IMPACT OF IMMUNOGENICITY ON THE QUANTITATION AND DISPOSITION OF A HUMAN MONOCLONAL ANTIBODY THERAPEUTIC IN MONKEYS
    Wang, Huifen Faye
    Lovering, Jeannine
    Soderstrom, Catherine
    Guo, Xiuling
    Finco-Kent, Deborah
    DRUG METABOLISM REVIEWS, 2008, 40 : 72 - 73
  • [9] Clinical Immunogenicity Risk Assessment Strategy for a Low Risk Monoclonal Antibody
    Robert Kernstock
    Gizette Sperinde
    Deborah Finco
    Roslyn Davis
    Diana Montgomery
    The AAPS Journal, 22
  • [10] Clinical Immunogenicity Risk Assessment Strategy for a Low Risk Monoclonal Antibody
    Kernstock, Robert
    Sperinde, Gizette
    Finco, Deborah
    Davis, Roslyn
    Montgomery, Diana
    AAPS JOURNAL, 2020, 22 (03):
12345